TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28088223
Drug: Early integrated
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early integrated treatment
Study: 24079817
Drug: Aqueous intranasal
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous intranasal corticosteroid (INS) formulation
Study: 24079817
Drug: Aerosol intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol intranasal corticosteroid (INS) formulation
Study: 24079817
Drug: Allergic Rhinitis
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergic Rhinitis Treatment Satisfaction and Preference (ARTSP) scale
Study: 24079817
Drug: Treatment satisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment satisfaction subscales
Study: 21865946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of p53 and v-Ki-ras2 mutations
Study: 21865946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of p53 and either v-Ki-ras2 mutation or cyclin D1 G870A (AA) polymorphism or methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT) polymorphism
Study: 19262477
Drug: Olmesartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan + Calcium Channel Blocker (ARB/CCB group)
Study: 19262477
Drug: Olmesartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan + Diuretic (ARB/diuretic group)
Study: 11737955
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (100 mg dl-alpha-tocopheryl acetate, 200 mg ascorbic acid, 2 mg beta-carotene)
Study: 8112368
Drug: Didanosine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine as a single agent
Study: 8112368
Drug: Didanosine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine with metoclopramide (10 mg IV)
Study: 8112368
Drug: Didanosine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine with loperamide (4 doses of 4 mg each)
Study: 27640067
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg SCH 527123
Study: 22119219
Drug: 2-L PEG+ascorbic
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L PEG+ascorbic acid
Study: 28939500
Drug: 4-L PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-L PEG
Study: 20102922
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg once per day
Study: 20102922
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg once per day
Study: 15823184
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beclomethasone dipropionate 250 microg b.i.d and slow-release theophylline 0.2 g b.i.d (SRT/BDP group)
Study: 10614676
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined 2 mg estradiol and 1 mg norethisterone acetate (E+NETA) daily
Study: 8540760
Drug: Zidovudine 50
Normalized name: ZIDOVUDINE 50MG/5ML SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 50 mg, 100 mg, 200 mg combined with Didanosine 67 mg, 167 mg, 250 mg
Study: 1784148
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (specific drugs not mentioned)
Study: 7092500
Drug: Schedule for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule for Affective Disorders and Schizophrenia‐Lifetime (SADS‐L)
Study: 7092500
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of SADS‐L and NIMH‐DIS
Study: 27730198
Drug: Umeclidinium 62.5
Normalized name: UMECLIDINIUM 62.5MCG 7D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium 62.5 µg
Study: 27730198
Drug: Glycopyrronium 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium 50 µg
Study: 24284985
Drug: 5% cis-urocanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% cis-urocanic acid emulsion cream
Study: 19156355
Drug: Atomoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (up to 1.2 mg/kg/day or 80 mg/day) with psychoeducation
Study: 18087899
Drug: Low Intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Intensity Laser Therapy (LILT)
Study: 12616983
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive preparations (30 micrograms ethinylestradiol with either 75 micrograms gestodene or 150 micrograms desogestrel)
Study: 12616983
Drug: 17 beta-oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-oestradiol (2 mg)
Study: 12616983
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive preparations (30 micrograms ethinylestradiol)
Study: 336002
Drug: L-5-hydroxytryptophan (L-5-HTP)
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (L-5-HTP)
Study: 8819814
Drug: Flecainide 150‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 150‐300 mg/die
Study: 8819814
Drug: Propafenone 450‐900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 450‐900 mg/die
Study: 2048373
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control group (N = 4)
Study: 22525561
Drug: Early endoscopic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early endoscopic treatment within 72 hours after initial symptom
Study: 22525561
Drug: No endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endoscopic treatment (control group)
Study: 20389025
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of insulin (0.1 IU/kg)
Study: 7071350
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate (80 mg/kg)
Study: 7071350
Drug: Intramuscular preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular preparation (AMPS: atropine, meperidine, promethazine, secobarbital)
Study: 26203171
Drug: School-based drug-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based drug-treatment and health-education intervention
Study: 17192324
Drug: Rosiglitazone (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (2-4 mg/day)
Study: 17192324
Drug: Rosiglitazone (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (high-dose 8 mg/day)
Study: 7846291
Drug: Psychotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapeutic treatment alongside practical care, initiated during pregnancy and conducted in mothers' homes on a long-term basis.
Study: 3044800
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment (induction scheme q 8 weeks)
Study: 28328179
Drug: Delayed-release dimethyl
Normalized name: dimethyl fumarate Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily
Study: 28783872
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (OC; norgestimate 250 μg, ethinyl estradiol 35 μg)
Study: 24029542
Drug: Warfarin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosing algorithm with daily INR measurements
Study: 19465443
Drug: IFNbeta‐1a 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 30 microg IM once weekly
Study: 19465443
Drug: IFNbeta‐1a 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 30 microg IM once weekly plus AZA 50 mg orally once daily
Study: 19465443
Drug: IFNbeta‐1a 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 30 microg IM once weekly plus AZA 50 mg orally once daily plus prednisone 10 mg orally every other day
Study: 11567748
Drug: Low-dose diphtheria-tetanus
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose diphtheria-tetanus vaccine (dT)
Study: 11567748
Drug: Standard paediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard paediatric dose (DT)
Study: 7843201
Drug: Single or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of natural porcine surfactant (Curosurf)
Study: 7843201
Drug: Single-dose surfactant
Normalized name: surfactant protein-D homotrimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose surfactant treatment
Study: 7843201
Drug: Multiple-dose surfactant
Normalized name: surfactant protein-D homotrimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose surfactant treatment
Study: 28514945
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment performed
Study: 23478662
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg, 3 times daily for 12 weeks, followed by 60 mg, 3 times daily for 12 weeks)
Study: 18315784
Drug: DTIC (2200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC (2200 mg/kg orally daily for 5 days, every 3 weeks)
Study: 18315784
Drug: DTIC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC + CCNU (DTIC at 2200 mg/kg and CCNU at 120 mg/m2 once every 40 days)
Study: 17023870
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate 1.25 mg
Study: 17023870
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate 2.5 mg
Study: 17023870
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate 5.0 mg
Study: 17023870
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate 7.5 mg
Study: 17023870
Drug: Increasing dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing dose of methylphenidate
Study: 9722817
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) with free treatment for 90 days
Study: 9722817
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) without free treatment
Study: 9722817
Drug: Risk reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk reduction (RR) with free treatment for 90 days
Study: 9722817
Drug: Risk reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk reduction (RR) without free treatment
Study: 7987510
Drug: Oral sumatriptan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sumatriptan, 100 mg
Study: 7987510
Drug: Subcutaneous sumatriptan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan, 6 mg
Study: 7987510
Drug: Combined subcutaneous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined subcutaneous and oral administration of sumatriptan
Study: 31340565
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% + 100 mg Tramadol (2 mL)
Study: 31340565
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% + 2 mL NaCl 0.9% (placebo)
Study: 18461664
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (Healive); 1 dose administered to 108 individuals and 3365 students.
Study: 18461664
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (Healive); 1 dose administered to 3365 students.
Study: 12135299
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 IU) administered preoperatively, with 2 or 3 doses depending on the procedure, along with oral iron for 14 or 21 days.
Study: 9375348
Drug: Sequential exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential exercise day (SEB; at 1000, 1130, and 1300)
Study: 9375348
Drug: Sequential exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential exercise day (SEB)
Study: 7902470
Drug: H2-blockers (Histadyl)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2-blockers (Histadyl)
Study: 7902470
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance therapy with drugs improving local microcirculation and stimulating bicarbonates production in gastric mucosa (synthetic prostaglandins analogues)
Study: 30335135
Drug: Rotavac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavac vaccine (monovalent human-bovine 116E)
Study: 29617381
Drug: PEG treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG treatment (both doses combined)
Study: 25208561
Drug: Flavonoid-rich dark
Normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich dark chocolate (50 g)
Study: 25208561
Drug: Placebo chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo chocolate (50 g)
Study: 21811866
Drug: Monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly ibandronate treatment for 12 months
Study: 16911813
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Orlistat and Fenofibrate
Study: 15951101
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg oral misoprostol every 4 h
Study: 12030962
Drug: Alverine citrate
Normalized name: alverine citrate
DrugBank: Alverine (DB01616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alverine citrate (120 mg capsule, three times daily for 12 weeks)
Study: 7741779
Drug: Mexiletine-ratiopharm mite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine-ratiopharm mite (200 mg)
Study: 7741779
Drug: Commercial reference
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial reference preparation
Study: 25892165
Drug: Treatment manual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment manual (TM)
Study: 23795737
Drug: Acetazolamide (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (125 mg bid)
Study: 23795737
Drug: Gingko biloba
Normalized name: Gingko Biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gingko biloba (120 mg bid)
Study: 20153154
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing 200mg red yeast rice extract and 10mg policosanols once-daily for 8 weeks
Study: 17704425
Drug: CRT‐IA (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT‐IA (150 mg/m², four courses) with sodium thiosulfate
Study: 17704425
Drug: CRT‐IV (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT‐IV (100 mg/m², three courses) without sodium thiosulfate
Study: 15073851
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and Paclitaxel (CP) - Paclitaxel at a dose of 225 mg/m² and carboplatin (AUC of 6) every 21 days
Study: 15073851
Drug: Methotrexate, Vinblastine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) - standard dosage
Study: 11560562
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) with ABC and ASA
Study: 11560562
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) with T and ASA
Study: 11560562
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (reviparin, REV) with ABC and ASA
Study: 11560562
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (reviparin, REV) with T and ASA
Study: 31710593
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage (15-min twice a day for 3 days)
Study: 30987668
Drug: EPA and
Normalized name: Norwegian Cod Liver Oil With EPA and DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA and DHA supplementation (600 mg EPA and 260 mg DHA per day for 8 weeks)
Study: 28389552
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg TCZ + MTX
Study: 28389552
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg TCZ + MTX
Study: 19785727
Drug: Financial incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial incentive for each anti-psychotic depot medication received over a 12 month period
Study: 11499801
Drug: Inhibitor titer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor titer < 2.0 U/mL
Study: 11499801
Drug: Inhibitor titer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor titer >= 2.0 U/mL
Study: 31542384
Drug: Levoketoconazole, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levoketoconazole, starting at 150 mg twice daily, titrated up to a maximum of 600 mg twice daily during a 2-21 week dose-titration phase followed by a 6-month maintenance phase.
Study: 31542384
Drug: Levoketoconazole treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levoketoconazole treatment
Study: 26464000
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of dexmedetomidine (DEX) 0.8 μg · kg‐1 · min‐1
Study: 19388120
Drug: Gadolinium doped
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium doped saline flush (50 mM gadolinium, total Gd: 0.11 mmol/kg, flow-rate: 2 mL/s)
Study: 19388120
Drug: Pure saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure saline flush (0.9% saline solution)
Study: 14983408
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + recombinant human growth hormone (rhGH) (daily dose 9.5 microg/kg body weight)
Study: 25802471
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Placebo
Study: 10450619
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) led by professional therapists
Study: 10450619
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) led by paraprofessional therapists
Study: 10450619
Drug: Mutual Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutual Support Group Therapy (MSG) led by professional therapists
Study: 10450619
Drug: Mutual Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutual Support Group Therapy (MSG) led by paraprofessional therapists
Study: 7570730
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (1 g/kg body wt)
Study: 7570730
Drug: Oral xylose
Normalized name: Xylose
DrugBank: Xylose (DB09419)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral xylose (0.83 g/kg)
Study: 732296
Drug: 4 pollen
Normalized name: POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 pollen extract capsules
Study: 732296
Drug: 4 protein
Normalized name: ABCB4 protein, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 protein extract capsules
Study: 732296
Drug: 4 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 placebo capsules
Study: 22027860
Drug: 12-week medicine
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week medicine ball training program
Study: 11309322
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of TNF with 1.5 mg/kg melphalan
Study: 11309322
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg melphalan alone
Study: 1259120
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine administered 5 minutes before surgery to half of the patients (25 patients).
Study: 1259120
Drug: Intramuscular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketamine without atropine (unatropinised group, 25 patients).
Study: 22057076
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg intravenous, starting from the 3rd week of transplantation for 3 months)
Study: 22057076
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg oral per week for 3 months)
Study: 19735523
Drug: Daytime SPF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime SPF 30 lotion
Study: 19735523
Drug: Night cream
Normalized name: Eucerin Q10 Anti-Wrinkle + Pro Retinol Night Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night cream
Study: 19735523
Drug: Eye cream
Normalized name: EYE CREAM
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eye cream
Study: 19735523
Drug: Wrinkle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrinkle treatment
Study: 11308999
Drug: 8 ng.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ng. ml‐1 plasma remifentanil
Study: 11308999
Drug: 4 ng.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ng. ml‐1 plasma remifentanil (Control)